N/A Completed N=25

Sleep Timing and Insulin Resistance in Adolescents With Obesity

Obesity

Source: ClinicalTrials.gov NCT02585830 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2020

Primary outcomePrimary: Dim Light Melatonin Onset and Offset — 21.33; 8.32 decimal hours

Summary

This study examines the relationship between sleep timing and insulin resistance in adolescents with obesity. The investigators also aim to develop a physiologically-based mathematical model of adolescent sleep/wake and circadian interactions.

Outcome Measures

Outcome	Result	p-value
PRIMARY Dim Light Melatonin Onset and Offset	21.33; 8.32	—
PRIMARY Insulin Sensitivity	2.9; 4.93	—

Eligibility Criteria

Inclusion Criteria

High school students between the ages of 15-19
BMI > 90th percentile
Tanner stage 2 or greater

Exclusion Criteria

Any medications that affect insulin resistance or sleep (e.g., metformin, hormonal contraception, stimulants, atypical antipsychotics)
Regular use of melatonin or sleep aids
A prior diagnosis of obstructive sleep apnea, diabetes (HbA1c > 6.5), liver disease other than non-alcoholic fatty liver disease, pregnancy or breastfeeding
IQ < 70 or severe mental illness that may impact sleep (e.g., schizophrenia, psychotic episodes)
Not enrolled in a traditional high school academic program (e.g., home school students)
Night shift employment
Travel across more than 2 time zones in the month prior to the study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02585830). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.